TABLE 3.

Initial assumptions on effectiveness of TDM interventions in GVHD population for model 2

Quartile	Posaconazole exposure (ng/ml) (median [range])	% of patients remaining in quartiles of posaconazole exposure after TDM intervention
		No TDMa	Minimally effective	Moderately effective	Maximally effective
Oral suspension
Quartile 1	289 (21.5–557)	25	15	5	0
Quartile 2	736 (557–915)	25	30	25	15
Quartile 3	1,239 (915–1,563)	25	30	40	55
Quartile 4	2,607 (1,563–3,650)	25	25	30	30
Tablet
Quartile 1	289 (21.5–557)	5	2.5	0	0
Quartile 2	736 (557–915)	5	7.5	5	0
Quartile 3	1,239 (915–1,563)	60	60	65	60
Quartile 4	2,607 (1,563–3,650)	30	30	30	40

^aDistribution of posaconazole plasma concentrations were derived from pharmacokinetic/pharmacodynamic analysis by Jang et al. (8) and Cornely et al. (14).